{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:53:29Z","timestamp":1791312809110,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02893-1","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:03:50Z","timestamp":1778072630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reduced levels of ITGB1 cause activation of p38MAPK-ERK-LYN axis of BCR::ABL1 signaling despite inactivation of the oncoprotein by imatinib \u2013 novel resistance mechanism in blast crisis of chronic myeloid leukemia unraveled"],"prefix":"10.1186","volume":"24","author":[{"given":"Neha","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythreyi","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mojidra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Gokarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Punattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukmini","family":"Govekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2893_CR1","first-page":"616","volume":"4","author":"R Garcia-Gomez","year":"2018","unstructured":"Garcia-Gomez R, Bustelo XR, Crespo P. Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway, Trends. Cancer. 2018;4:616\u201333.","journal-title":"Cancer"},{"key":"2893_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41419-024-07079-6","volume":"15","author":"JZ Jiang","year":"2024","unstructured":"Jiang JZ, Qiao YB, Zhu XR, Gu QH, Lu JJ, Ye ZY, et al. Identification of Galphai3 as a promising molecular oncotarget of pancreatic cancer. Cell Death Dis. 2024;15:699.","journal-title":"Cell Death Dis"},{"key":"2893_CR3","doi-asserted-by":"publisher","first-page":"13899","DOI":"10.18632\/oncotarget.4224","volume":"6","author":"A Gonnissen","year":"2015","unstructured":"Gonnissen A, Isebaert S, Haustermans K. Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened. Oncotarget. 2015;6:13899\u2013913.","journal-title":"Oncotarget"},{"key":"2893_CR4","doi-asserted-by":"publisher","first-page":"649434","DOI":"10.3389\/fcell.2021.649434","volume":"9","author":"TT Huang","year":"2021","unstructured":"Huang TT, Wang X, Qiang SJ, Zhao ZN, Wu ZX, Ashby CR Jr, et al. The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach. Front Cell Dev Biol. 2021;9:649434.","journal-title":"Front Cell Dev Biol"},{"key":"2893_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.yexmp.2018.02.005","volume":"104","author":"X Qing","year":"2018","unstructured":"Qing X, Qing A, Ji P, French SW, Mason H. Mixed phenotype (T\/B\/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia. Exp Mol Pathol. 2018;104:130\u20133.","journal-title":"Exp Mol Pathol"},{"key":"2893_CR6","doi-asserted-by":"publisher","first-page":"e7661","DOI":"10.1371\/journal.pone.0007661","volume":"4","author":"X Zheng","year":"2009","unstructured":"Zheng X, Oancea C, Henschler R, Moore MA, Ruthardt M. Reciprocal t(9;22) ABL\/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS ONE. 2009;4:e7661.","journal-title":"PLoS ONE"},{"key":"2893_CR7","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.","journal-title":"Chemother Res Pract"},{"key":"2893_CR8","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928\u201337.","journal-title":"Blood"},{"key":"2893_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1080\/10428190500525607","volume":"47","author":"M Miglino","year":"2006","unstructured":"Miglino M, Grasso R, Varaldo R, Fugazza G, Colombo N, Clavio M, et al. Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia. Leuk Lymphoma. 2006;47:1348\u201351.","journal-title":"Leuk Lymphoma"},{"key":"2893_CR10","doi-asserted-by":"publisher","first-page":"e2015014","DOI":"10.4084\/mjhid.2015.014","volume":"7","author":"IC Haznedaroglu","year":"2015","unstructured":"Haznedaroglu IC. Drug Therapy in the Progressed CML Patient with multi-TKI Failure. Mediterr J Hematol Infect Dis. 2015;7:e2015014.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2893_CR11","doi-asserted-by":"publisher","unstructured":"Yohannan B, George B. B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms231911836.","DOI":"10.3390\/ijms231911836"},{"key":"2893_CR12","doi-asserted-by":"publisher","unstructured":"Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program. 2009:461\u2013476. https:\/\/doi.org\/10.1182\/asheducation-2009.1.461.","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"2893_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.leukres.2014.12.008","volume":"39","author":"R Alves","year":"2015","unstructured":"Alves R, Fonseca AR, Goncalves AC, Ferreira-Teixeira M, Lima J, Abrantes AM, et al. Drug transporters play a key role in the complex process of Imatinib resistance in vitro. Leuk Res. 2015;39:355\u201360.","journal-title":"Leuk Res"},{"key":"2893_CR14","first-page":"981","volume":"64","author":"N Takahashi","year":"2023","unstructured":"Takahashi N. Next treatment for TKI-resistant CML. Rinsho Ketsueki. 2023;64:981\u20137.","journal-title":"Rinsho Ketsueki"},{"key":"2893_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/nyas.14298","volume":"1467","author":"T Lu","year":"2020","unstructured":"Lu T, Wei D, Yu K, Ma D, Xiong J, Fang Q, et al. Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation. Ann N Y Acad Sci. 2020;1467:77\u201393.","journal-title":"Ann N Y Acad Sci"},{"key":"2893_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O\u2019Hare T, Deininger MW. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. Hematol Oncol Clin North Am. 2017;31:589\u2013612.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2893_CR17","doi-asserted-by":"publisher","unstructured":"Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14143300.","DOI":"10.3390\/cancers14143300"},{"key":"2893_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12079-021-00647-x","volume":"16","author":"M Narasimhan","year":"2022","unstructured":"Narasimhan M, Khamkar V, Tilwani S, Dalal SN, Shetty D, Subramanian PG, et al. Atypical activation of signaling downstream of inactivated Bcr-Abl mediates chemoresistance in chronic myeloid leukemia. J Cell Commun Signal. 2022;16:207\u201322.","journal-title":"J Cell Commun Signal"},{"key":"2893_CR19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1046\/j.1365-2141.2001.03192.x","volume":"115","author":"R Bhatia","year":"2001","unstructured":"Bhatia R, Munthe HA, Forman SJ. Abnormal growth factor modulation of beta1-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors. Br J Haematol. 2001;115:845\u201353.","journal-title":"Br J Haematol"},{"key":"2893_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1172\/JCI117333","volume":"94","author":"R Bhatia","year":"1994","unstructured":"Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest. 1994;94:384\u201391.","journal-title":"J Clin Invest"},{"key":"2893_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12964-023-01338-3","volume":"22","author":"C Su","year":"2024","unstructured":"Su C, Mo J, Dong S, Liao Z, Zhang B, Zhu P. Integrinbeta-1 in disorders and cancers: molecular mechanisms and therapeutic targets. Cell Commun Signal. 2024;22:71.","journal-title":"Cell Commun Signal"},{"key":"2893_CR22","doi-asserted-by":"crossref","unstructured":"Meenakshi Sundaram DN, Kucharski C, Bahadur Kc R, Tarman IO, Uludag H. Polymeric siRNA delivery targeting integrin-beta1 could reduce interactions of leukemic cells with bone marrow microenvironment. Biomater Biosyst. 2021;3:100021.","DOI":"10.1016\/j.bbiosy.2021.100021"},{"key":"2893_CR23","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3109\/10428191003746315","volume":"51","author":"W Guo-Bao","year":"2010","unstructured":"Guo-Bao W, Xiao-Qin C, Qi-Rong G, Jie L, Gui-Nan L, Yue L. Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line. Leuk Lymphoma. 2010;51:1090\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2893_CR24","doi-asserted-by":"crossref","unstructured":"Mojidra R, Gardi N, Bagal B, Khattry N, Gokarn A, Punatar S, Govekar R. Genomic analysis identifies an incipient signature to forecast imatinib resistance before start of treatment in patients with chronic myeloid leukemia. Adv Biomarker Sci Technol. 2025;7:59\u201364.","DOI":"10.1016\/j.abst.2025.01.004"},{"key":"2893_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248\u201354.","journal-title":"Anal Biochem"},{"key":"2893_CR26","doi-asserted-by":"crossref","unstructured":"Neha Agrawal RG. Incremental Modification in the Existing Approaches for Affinity Chromatographic Enrichment of Phosphoproteins Improves Their Profile in Liquid Chromatography-Tandem Mass Spectrometry Analysis. Anal Sci Adv. 2024. https:\/\/chemistry-europe.onlinelibrary.wiley.com\/doi\/full\/10.1002\/ansa.202400058.","DOI":"10.1002\/ansa.202400058"},{"key":"2893_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12967-019-1937-9","volume":"17","author":"M Narasimhan","year":"2019","unstructured":"Narasimhan M, Kannan S, Chawade A, Bhattacharjee A, Govekar R. Clinical biomarker discovery by SWATH-MS based label-free quantitative proteomics: impact of criteria for identification of differentiators and data normalization method. J Transl Med. 2019;17:184.","journal-title":"J Transl Med"},{"key":"2893_CR28","doi-asserted-by":"crossref","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo S, Bork P, Jensen LJ, von Mering C. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638-D646.","DOI":"10.1093\/nar\/gkac1000"},{"key":"2893_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nature10575","volume":"480","author":"JC Tran","year":"2011","unstructured":"Tran JC, Zamdborg L, Ahlf DR, Lee JE, Catherman AD, Durbin KR, et al. Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature. 2011;480:254\u20138.","journal-title":"Nature"},{"key":"2893_CR30","first-page":"2343","volume":"61","author":"E Laurent","year":"2001","unstructured":"Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001;61:2343\u201355.","journal-title":"Cancer Res"},{"key":"2893_CR31","doi-asserted-by":"crossref","unstructured":"Khadilkar RJ, Ho KYL, Venkatesh B, Tanentzapf G. Integrins Modulate Extracellular Matrix Organization to Control Cell Signaling during Hematopoiesis. Curr Biol. 2020;30:3316\u20133329 e3315.","DOI":"10.1016\/j.cub.2020.06.027"},{"key":"2893_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/bs.ctdb.2022.02.009","volume":"149","author":"PW Krenn","year":"2022","unstructured":"Krenn PW, Montanez E, Costell M, Fassler R. Integrins, anchors and signal transducers of hematopoietic stem cells during development and in adulthood. Curr Top Dev Biol. 2022;149:203\u201361.","journal-title":"Curr Top Dev Biol"},{"key":"2893_CR33","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41375-023-01929-6","volume":"37","author":"Y Chen","year":"2023","unstructured":"Chen Y, Mobius S, Riege K, Hoffmann S, Hochhaus A, Ernst T, et al. Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution. Leukemia. 2023;37:1561\u20136.","journal-title":"Leukemia"},{"key":"2893_CR34","doi-asserted-by":"publisher","unstructured":"Brown G. Hematopoietic and Chronic Myeloid Leukemia Stem Cells: Multi-Stability versus Lineage Restriction. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms232113570.","DOI":"10.3390\/ijms232113570"},{"key":"2893_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.arcmed.2003.09.005","volume":"34","author":"AL Petzer","year":"2003","unstructured":"Petzer AL, Gunsilius E. Hematopoietic stem cells in chronic myeloid leukemia. Arch Med Res. 2003;34:496\u2013506.","journal-title":"Arch Med Res"},{"key":"2893_CR36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0022-2143(97)90192-X","volume":"129","author":"CM Verfaillie","year":"1997","unstructured":"Verfaillie CM, Hurley R, Zhao RC, Prosper F, Delforge M, Bhatia R. Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR\/ABL positive clone? J Lab Clin Med. 1997;129:584\u201391.","journal-title":"J Lab Clin Med"},{"key":"2893_CR37","doi-asserted-by":"publisher","first-page":"10538","DOI":"10.1073\/pnas.190104497","volume":"97","author":"Y Jiang","year":"2000","unstructured":"Jiang Y, Zhao RC, Verfaillie CM. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR\/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci U S A. 2000;97:10538\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2893_CR38","doi-asserted-by":"crossref","unstructured":"Rothe K, Babaian A, Nakamichi N, Chen M, Chafe SC, Watanabe A, Forrest DL, Mager DL, Eaves CJ, Dedhar S, Jiang X. Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors. Cell Stem Cell. 2020;27:110\u2013124 e119.","DOI":"10.1016\/j.stem.2020.04.005"},{"key":"2893_CR39","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/leu.2008.187","volume":"23","author":"JW Tyner","year":"2009","unstructured":"Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, et al. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia. 2009;23:406\u20139.","journal-title":"Leukemia"},{"key":"2893_CR40","doi-asserted-by":"publisher","first-page":"e13420","DOI":"10.1111\/cpr.13420","volume":"56","author":"M Tsubaki","year":"2023","unstructured":"Tsubaki M, Takeda T, Koumoto Y, Usami T, Matsuda T, Seki S, et al. Activation of ERK1\/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells. Cell Prolif. 2023;56:e13420.","journal-title":"Cell Prolif"},{"key":"2893_CR41","doi-asserted-by":"publisher","first-page":"9535","DOI":"10.1038\/s41598-017-10373-3","volume":"7","author":"A Kumar","year":"2017","unstructured":"Kumar A, Bhattacharyya J, Jaganathan BG. Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways. Sci Rep. 2017;7:9535.","journal-title":"Sci Rep"},{"key":"2893_CR42","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood.V124.21.1790.1790","volume":"124","author":"L Ma","year":"2014","unstructured":"Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, et al. PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia. Blood. 2014;124:1790\u20131790.","journal-title":"Blood"},{"key":"2893_CR43","doi-asserted-by":"publisher","unstructured":"Kuo YH, Wei SH, Jiang JH, Chang YS, Liu MY, Fu SL, Huang CF, Lin WJ. Perturbation of p38alpha MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms222212573.","DOI":"10.3390\/ijms222212573"},{"key":"2893_CR44","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/S0301-472X(99)00084-3","volume":"27","author":"R Bhatia","year":"1999","unstructured":"Bhatia R, Munthe HA, Verfaillie CM. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Exp Hematol. 1999;27:1384\u201396.","journal-title":"Exp Hematol"},{"key":"2893_CR45","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","volume":"111","author":"J Wu","year":"2008","unstructured":"Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood. 2008;111:3821\u20139.","journal-title":"Blood"},{"key":"2893_CR46","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.leu.2401429","volume":"13","author":"V Roginskaya","year":"1999","unstructured":"Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia. 1999;13:855\u201361.","journal-title":"Leukemia"},{"key":"2893_CR47","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690\u20138.","journal-title":"Blood"},{"key":"2893_CR48","doi-asserted-by":"crossref","unstructured":"Perez-Riverol Y, Bai J, Bandla C, Garcia-Seisdedos D, Hewapathirana S, Kamatchinathan S, Kundu DJ, Prakash A, Frericks-Zipper A, Eisenacher M, Walzer M, Wang S, Brazma A, Vizcaino JA. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50:D543-D552.","DOI":"10.1093\/nar\/gkab1038"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02893-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02893-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02893-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:37:50Z","timestamp":1782866270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02893-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2893"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02893-1","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study, which identified the key DEPs through genomic analysis of patient samples, validated in this study, was approved by the ethics committee of Tata Memorial Centre, India.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}